As of 2024-07-27, the Relative Valuation of Rigel Pharmaceuticals Inc (RIGL) is (34.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 10.75 USD, the upside of Rigel Pharmaceuticals Inc based on Relative Valuation is -416.5%.
The range of the Relative Valuation is (34.73) - (33.94) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 30.8x - 31.8x | 31.3x |
| Forward P/E multiples | 28.0x - 30.1x | 29.0x |
| Fair Price | (34.73) - (33.94) | (34.02) |
| Upside | -423.1% - -415.7% | -416.5% |
| Date | P/E |
| 2024-07-26 | -9.53 |
| 2024-07-25 | -9.67 |
| 2024-07-24 | -9.34 |
| 2024-07-23 | -9.34 |
| 2024-07-22 | -8.97 |
| 2024-07-19 | -8.57 |
| 2024-07-18 | -8.53 |
| 2024-07-17 | -9.18 |
| 2024-07-16 | -9.98 |
| 2024-07-15 | -9.39 |
| 2024-07-12 | -8.85 |
| 2024-07-11 | -8.53 |
| 2024-07-10 | -7.62 |
| 2024-07-09 | -7.22 |
| 2024-07-08 | -6.98 |
| 2024-07-05 | -6.90 |
| 2024-07-03 | -6.86 |
| 2024-07-02 | -7.47 |
| 2024-07-01 | -7.46 |
| 2024-06-28 | -7.29 |
| 2024-06-27 | -8.45 |
| 2024-06-26 | -7.01 |
| 2024-06-25 | -7.47 |
| 2024-06-24 | -8.48 |
| 2024-06-21 | -8.43 |
| 2024-06-20 | -8.47 |
| 2024-06-18 | -8.01 |
| 2024-06-17 | -8.22 |
| 2024-06-14 | -8.45 |
| 2024-06-13 | -8.64 |
| 2024-06-12 | -8.87 |
| 2024-06-11 | -9.05 |
| 2024-06-10 | -9.05 |
| 2024-06-07 | -8.43 |
| 2024-06-06 | -8.51 |
| 2024-06-05 | -8.67 |
| 2024-06-04 | -8.64 |
| 2024-06-03 | -8.72 |
| 2024-05-31 | -8.67 |
| 2024-05-30 | -8.31 |
| 2024-05-29 | -8.14 |
| 2024-05-28 | -8.26 |
| 2024-05-24 | -8.05 |
| 2024-05-23 | -8.01 |
| 2024-05-22 | -8.18 |
| 2024-05-21 | -8.11 |
| 2024-05-20 | -8.47 |
| 2024-05-17 | -8.43 |
| 2024-05-16 | -8.71 |
| 2024-05-15 | -8.60 |